{"prompt": "['Product: MK-3475', '65', 'Protocol/Amendment No.: 604-09', 'Screening', 'End of', 'Follow-up', 'Phase', 'Treatment Phase (3-Week Cycles)', 'Treatment', 'PFS', 'Safety', 'Survival', 'Screening', 'Follow-', 'Treatment Cycle', '1', '1', '1', '2', '2', '2', '3', '3', '3', '4', '4', '4', '5-35', 'Discon\u00b9', 'Follow-', 'Follow-', '(Visit 1)', 'up\u00b2', 'up', 'Visits\u00b3', 'up4', 'Day (in Cycle)', '1', '2&3', '8', '1', '2&3', '8', '1', '2&3', '8', '1', '2&3', '8', '1', 'NA', 'NA', 'NA', 'NA', 'Every 6', 'or 9', '30 Days', 'Weeks', 'At Time of', 'From', 'Every 8', 'Scheduling Window', '-28 to -1', '+3', ' 1', '3', ' 1', '3', '1', '3', '1', '3', '( 7', 'Discon', 'Last', 'Weeks', '(Days):5', '3', 'Dose', 'days)', '7 days', '+7', 'per', 'imaging', 'schedule', 'Study Drug Administration23', 'Pembrolizumab or Saline', 'X', 'X', 'X', 'X', 'Placebo24', 'Carboplatin or Cisplatin25', 'X', 'X', 'X', 'X', 'Etoposide26', 'Patient Reported Outcomes27', 'EQ-5D-5L', 'X', 'X', 'X', 'X', 'X', 'EORTC QLQ-C30', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'EORTC QLQ-LC13', 'X', 'X', '1. The Discontinuation Visit should occur at the time study drug is discontinued for any reason. If the Discontinuation Visit occurs 30 days from the last', 'dose', 'of', 'study', 'treatment (ie, at the time of the mandatory Safety Follow up Visit), procedures required at both visits only need to be performed once.', '2.', 'The mandatory Safety Follow-up Visit for all subjects should be conducted approximately 30 days after the last dose of trial treatment or before the initiation of new', 'antineoplastic treatment, whichever comes first. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of', 'a new antineoplastic therapy, whichever occurs first. If the Discontinuation Visit occurs approximately 30 (3) days from last dose trial treatment the same procedures do', 'not need to be repeated for the Safety Follow-up Visit.', '3.', 'Subjects who discontinue from the treatment phase prior to disease progression will continue to be followed in PFS follow-up until they experience disease progression or', 'start a new antineoplastic therapy. Subjects with an AE of Grade >1 will be further followed until the resolution of the AE to Grade 0-1 or until beginning of a new', 'antineoplastic therapy, whichever occurs first.', '4.', 'Once the subject stops the imaging assessments (eg, for PD or starting a new antineoplastic therapy), the subject moves into the Survival Follow-up Phase and should be', \"contacted by telephone approximately every 8 weeks to assess for survival status. Post-study antineoplastic treatments and the subject's response to them will also be\", 'collected. Updated survival status may be requested by the Sponsor at any time during the course of the study. Upon Sponsor notification, all participants who do not/will', 'not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants', 'that', 'have', 'a', 'death', 'event previously recorded).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '66', 'Protocol/Amendment No.: 604-09', '5.', 'In general, the window for Day 1 of each cycle is 3 days unless otherwise noted. Days 1, 2, and 3 must be consecutive without interruption for Cycles 1 to 4; therefore,', 'there is no visit window for Days 2 and 3 during the first 4 cycles. If treatment cycles are adjusted, all procedures except imaging will be completed according to the cycle', 'number and not weeks on treatment; imaging will not be adjusted for delays in treatment cycles and will be performed per calendar schedule.', '6.', 'All concomitant medications received within 28 days before the first dose of trial treatment through the Safety Follow-up Visit (30 days after the last dose of trial', 'treatment) should be recorded. Serious AEs that occur within 90 days after the end of treatment or before initiation of a non-study anticancer treatment must be', 'documented and reported to the Sponsor immediately; after the Safety Follow-up Visit, all medications taken during the 14 days prior to an SAE and all medications taken', 'to treat the SAE must be recorded as defined in Section 7.2. All non-study antineoplastic treatments should be documented.', '7.', 'See Section 7.2.3.1 for details on reporting timeframe for SAEs.', '8.', 'Height will be measured only at Visit 1. Only if there is a change in weight of >10%, should the dose of chemotherapy administered during Cycles 1 to 4 change.', '9. ECOG for screening should be performed within 10 days prior to the first dose of trial treatment.', '10. Subjects in either arm who achieve CR or PR after Cycle 4 may be offered PCI at the discretion of the treating investigator. See Section 7.1.2.6 for details.', '11. For women of reproductive potential, a urine pregnancy test should be performed within 72 hours prior to first dose of trial treatment. A serum test can be considered if', 'urine is not appropriate. Monthly pregnancy testing should be conducted as per local regulations where applicable.', '12. Laboratory tests for screening are to be performed within 10 days prior to the first dose of trial treatment, with the exception of hepatitis serologies which may be', 'performed within 28 days of the first dose of trial treatment. Testing for Hepatitis B and Hepatitis C should be performed as mandated by the local health authority.', 'Starting with Cycle 1, laboratory safety tests must be conducted within 72 hours prior to the first dose of trial treatment in each cycle, with the exception of the thyroid', 'function tests and LDH, which may be conducted up to 10 days prior to first dose of trial treatment. Laboratory results must be known prior', 'to', 'dosing.', '13. Urinalysis is to be repeated every 6 cycles beginning at Cycle 6.', '14. Thyroid tests are to be repeated every 2 cycles beginning at Cycle 2.', '15. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. If there is either a documented law or regulation', 'prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes, then this sample will not be collected at that site. If the sample is', 'collected, leftover extracted DNA will be stored for Future Biomedical Research if the subject signs the Future Biomedical Research consent. If the planned genetic', 'analysis is not approved, but Future Biomedical Research is approved and consent is given, this sample will be collected for the purpose of Future Biomedical Research.', '16. CT with contrast (preferred) of the chest, abdomen and pelvis is required for all subjects; non-contrast CT of the chest and MRI of the abdomen and pelvis may be used', 'for subjects in whom iodinated contrast is contraindicated.', '17. Tumor imaging to be performed every 6 weeks (42 [+ 7] days) for the first 48 weeks of treatment from the date of randomization, then every 9 weeks (63 [= 7] days)', 'subsequently until documented disease progression, or the start of new anti-cancer treatment. Refer to Section 7.1.2.7 for additional details. Imaging is to follow calendar', 'days regardless of any delays in dosing. For patients treated beyond progression of disease as verified by BICR, the timing of imaging should continue from the date of', 'randomization (every 6 weeks (42 [+ 7] days) for the first 48 weeks, then every 9 weeks (63 [+ 7] days) or at shorter intervals, as deemed necessary by the investigator).', '18. If previous tumor imaging was obtained within 4 weeks prior to the date of discontinuation, then tumor imaging at treatment discontinuation is not mandatory.', '19. MRI (strongly preferred) or CT with contrast of the brain at baseline for all subjects. For subjects without brain metastases at diagnosis, brain imaging is required prior to', 'initiating PCI and as clinically indicated. For subjects with brain metastases at diagnosis that have undergone treatment, repeat brain imaging is to be performed at all post-', 'baseline imaging assessments.', '20. MRI (strongly preferred) or CT with contrast of the brain for subjects with metastases at diagnosis that have undergone treatment, repeat brain imaging is to be performed', 'at all post-baseline imaging assessments.', '21. MRI (strongly preferred) or CT with contrast of the brain for all subjects prior to initiating PCI.', '22. Nuclear Medicine bone scan for all subjects, at baseline, to assess for bone lesions. Bone scan is to be repeated in patients with bone lesions at baseline who achieve a', 'radiographic CR (to confirm osseous response) and as clinically indicated.', '23. Study drug administration should begin on the day of randomization, but no later than 3 days after randomization.', '24. Pembrolizumab 200 mg (or saline placebo) will be administered as a 30-minute IV infusion every 3 weeks (Q3W) for up to 35 cycles. During Cycles 1 to 4', 'pembrolizumab (or saline placebo) will be administered prior to administration of chemotherapy.', '25. Carboplatin dosed to a target AUC of 5 and cisplatin 75 mg/m\u00b2 will be administered as an IV infusion over approximately 60 minutes Q3W and over 30 to 180 minutes', 'Q3W, respectively, on Day 1. Dose should be recalculated if there is a >10% weight change.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}